High Roller Technologies provides update on Q2 performance
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ROLR:
Disclaimer & DisclosureReport an Issue
High Roller submits gaming license application in Ontario
High Roller Technologies Appoints New CFO Amid Leadership Change
High Roller Technologies appoints Felman as CFO
High Roller Technologies Reports Q1 2025 Earnings
High Roller Technologies appoints Seth Young as SVP, corporate strategy and IR
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
24 minutes ago
- Business Wire
Telix Pharmaceuticals Limited Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights
LOS ANGELES--(BUSINESS WIRE)-- The DJS Law Group announces that it is investigating claims on behalf of investors of Telix Pharmaceuticals Limited ('Telix' or 'the Company') (NASDAQ: TLX) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. On July 22, 2025, Telix disclosed it was the subject of a subpoena from the SEC "seeking various documents and information primarily relating to the Company's disclosures regarding the development of the Company's prostate cancer therapeutic candidates." Telix ADRs fell by more than 10.4% on July 23, 2025, based on this disclosure. If you are a shareholder who suffered a loss, contact us to participate. WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Yahoo
an hour ago
- Yahoo
NexMetals Drills 19.40 Metres of 3.93% CuEq Including 4.02% CuEq Over 13.55 Metres Showing Continuity of High-Grade Mineralization in the Expansion of the Selebi North Deposit
Vancouver, British Columbia--(Newsfile Corp. - August 21, 2025) - NexMetals Mining Corp. (TSXV: NEXM) (NASDAQ: NEXM) (the "Company" or "NEXM") reports assay results from an additional drill hole successfully intersecting high-grade mineralization at the Selebi North Underground ("SNUG") deposit. Drill hole SNUG-25-189 was designed to test the continuity of mineralization and confirms a significant extension of the South Limb and N2 mineralization. Highlights Drill Hole SNUG-25-189: intersected South Limb and N2 Limb (Figure 1) South Limb: 4.90 metres of 4.39% CuEq (0.73% Cu, 1.77% Ni)N2 Limb: 19.40 metres of 3.93% CuEq (1.05% Cu, 1.40 % Ni)Including: 13.55 metres of 4.02% CuEq (0.74% Cu, 1.60% Ni) Recent results confirm that the mineralization continues at greater depths, strengthening confidence in the size and continuity of the deposit. Drilling is ongoing to evaluate the strike extent of this new mineralization, with assay results pending for SNUG-25-191, which intersected mineralization in South Limb. SNUG-25-192 currently in progress. Figure 1: Location of drill holes relative to the 2024 Mineral Resource Estimate and underground infrastructure. To view an enhanced version of this graphic, please visit: Morgan Lekstrom, CEO of the Company, commented: "Drilling continues to highlight consistent high-grade copper, nickel, and cobalt mineralization extending past the limits of the 2024 resource, reinforcing the potential for further expansion. These next holes including drill hole 189, are designed to evaluate the lateral extent of this mineralization and tie the datasets together, with the goal of increasing both the size and confidence of the deposit. Drilling is ongoing, and this release represents the first results from that program." Assay results have been received and reported below in Table 1 and drill hole collar details are provided in Table 2. Assays are pending for all other drill holes described herein. The various mineralized zones have been historically mined and subsequently named N2 Limb, N3 Limb and South Limb to demarcate their location on the folded mineralized horizon. Additional drilling is needed to properly determine true width of mineralization on each limb and define the folded mineralization. Table 1: Assay Results Selebi North Deposit Hole-ID From(m) To(m) Length(m)1 Cu(%) Ni(%) Co(%)2 Limb CuEq(%)3 SNUG-25-189 715.50 720.40 4.90 0.73 1.77 0.09 South Limb 4.39 SNUG-25-189 814.85 834.25 19.40 1.05 1.40 0.08 N2 3.93 incl 814.85 828.40 13.55 0.74 1.60 0.09 N2 4.02 incl 814.85 820.40 5.55 0.89 1.90 0.10 N2 4.81 and 831.40 834.25 2.85 2.86 0.88 0.05 N2 4.68 1Length refers to drillhole length and not true width. True widths are unknown.2Co is not included in the MRE as cobalt analyses are not consistently available throughout the deposit. 3CuEq was calculated using the formula CuEq=Cu+2.06*Ni assuming long-term prices of US$10.50/lb Ni and US$4.75/lb Cu, and nickel and copper recoveries of 72.0% and 92.4%, respectively, derived from metallurgical studies which consider a conceptual bulk concentrate scenario. Table 2: Drill Collar Information Selebi North Deposit HOLE ID Mine East Mine North Elevation Dip MineAzimuth Hole Length Comment SNUG-25-189 35368.1 84409.7 81.1 -60.9 167.5 1028.5 Rig #2 810mL P5 Qualified Person All scientific and technical information in this news release has been reviewed and approved by Sharon Taylor, VP Exploration of the Company, MSc, and a "qualified person" for the purposes of National Instrument 43-101 and Subpart 1300 of Regulation S-K. Quality Control Drill core samples are BQTK (40.7 mm diameter). All samples are ½ core cut by a diamond saw on site. Half of the core is retained for reference purposes. Samples are generally 1.0 to 1.5 metre intervals or less at the discretion of the site geologists. Sample preparation and lab analysis was completed at ALS Chemex in Johannesburg, South Africa. Commercially prepared blank samples and certified Cu/Ni sulphide analytical control standards with a range of grades are inserted in every batch of 20 samples or a minimum of one set per sample batch. Analyses for Ni, Cu and Co are completed using a peroxide fusion preparation and ICP-AES finish (ME-ICP81). Holes are numbered as follows: SNUG (Selebi North Underground) + year + hole number starting at 013. Technical Report The MRE on the Selebi Mine is supported by the technical report entitled "Technical Report, Selebi Mines, Central District, Republic of Botswana" and dated September 20, 2024 (with an effective date of June 30, 2024) (the "Selebi Technical Report"), and prepared by SLR Consulting (Canada) Ltd. for NEXM. Reference should be made to the full text of the Selebi Technical Report, which was prepared in accordance with NI 43-101 and Subpart 1300 of Regulation S-K and is available on SEDAR+ ( and EDGAR ( in each case, under NEXM's issuer profile. About NexMetals Mining Corp. NexMetals Mining Corp. is a mineral exploration and development company that is focused on the redevelopment of the previously producing copper, nickel and cobalt resources mines owned by the Company in the Republic of Botswana. NexMetals is committed to governance through transparent accountability and open communication within our team and our stakeholders. NexMetals' team brings extensive experience across the full spectrum of mine discovery and development. Collectively, the team has contributed to dozens of projects, including work on the Company's Selebi and Selkirk mines. Senior team members each have on average, more than 20 years of experience spanning geology, engineering, operations, and project development. For further information about NexMetals Mining Corp., please contact: Morgan LekstromCEO and Directormorganl@ Jaclyn RuptashV.P., Communications and Investor Relationsjaclyn@ Follow Us X: LinkedIn: Facebook: Neither the TSX Venture Exchange and its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) nor the Nasdaq Stock Market LLC accepts responsibility for the adequacy or accuracy of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. Cautionary Note Regarding Forward-Looking Statements This news release contains "forward-looking statements" within the meaning of the United States federal securities laws and "forward-looking information" within the meaning of applicable Canadian securities legislation (collectively, "forward-looking information") based on expectations, estimates and projections as at the date of this news release. Forward-looking information involves risks, uncertainties and other factors that could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. For the purposes of this release, forward-looking information includes, but is not limited to: ongoing and expected drilling at SNUG; possible expanded mineralization beyond the existing MRE; the release of assay results and the expected timing thereof; the expectation the mineralized corridor continues at depth; the expected continuity and scale of the South Limb and N2 mineralized systems, the implementation of the objectives, goals and future plans of the Company including the proposed advancement of the Selebi Mine as currently contemplated; the expectation that exploration activities (including drill results) will accurately predict mineralization; the expectation that the Company will implement its drilling, geoscience and metallurgical work on its properties and work plans generally; the implementation of the objectives, goals and future plans of the Company including the proposed advancement of the Selebi Mine as currently contemplated; the effective targeting activities proposed by the Company; the benefits of the Company's approach to exploration; management's belief that the historical resource could be indicative of the presence of mineralization on the deposits; and the anticipated benefits of the Company's approach to the resource development plan. These forward-looking statements, by their nature, require the Company to make certain assumptions and necessarily involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in these forward-looking statements. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, capital and operating costs varying significantly from estimates; the preliminary nature of metallurgical test results; the ability of exploration results to predict mineralization, prefeasibility or the feasibility of mine production; the risk that mineralized corridor will not continue at depth; the risk that assay results will not be as anticipated or received when anticipated; the risk that continuity and scale of the South Limb and N2 mineralized systems will not be as expected; delays in obtaining or failures to obtain required governmental, environmental or other project approvals; uncertainties relating to the availability and costs of financing needed in the future; changes in equity markets; inflation; fluctuations in commodity prices; delays in the development of projects; the other risks involved in the mineral exploration and development industry; and those risks set out in the Company's filings with the U.S. Securities and Exchange Commission on EDGAR ( and public disclosure record on SEDAR+ ( in each case, under NEXM's issuer profile. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law. To view the source version of this press release, please visit
Business Wire
an hour ago
- Business Wire
Sarepta Therapeutics Announces Refinancing of Approximately $700 Million of 1.25% Convertible Senior Notes due 2027
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it has entered into separate, privately negotiated exchange agreements with a limited number of holders of its 1.25% convertible senior notes due 2027 (the 'Existing Convertible Notes') in each case pursuant to exemptions from registration under the Securities Act of 1933, as amended (the 'Securities Act'). Pursuant to the exchange agreements, the Company will exchange approximately $700.0 million in aggregate principal amount of the Existing Convertible Notes for approximately $602.0 million in aggregate principal amount of new 4.875% convertible senior notes due 2030 (the 'New Convertible Notes'), up to approximately 6.7 million shares of the Company's common stock, par value $0.001 per share ('Common Stock'), and approximately $123.3 million in cash (such exchanges, collectively, the 'Exchange'). The New Convertible Notes have an initial conversion rate of 16.6667 shares of Common Stock per $1,000 principal amount of New Convertible Notes (which is equivalent to an initial conversion price of approximately $60.00 per share of Common Stock), representing an approximately 191.5% conversion premium based on the last reported sale price of Common Stock of $20.58 per share on August 20, 2025. Additionally, the Company entered into a privately negotiated subscription agreement with J. Wood Capital Advisors LLC for the private placement of up to approximately 1.4 million shares of Common Stock (together with the Exchange, the 'Transactions'). "This exchange marks important progress in our long-term financial strategy," said Doug Ingram, chief executive officer, Sarepta. "By extending the maturity of a meaningful portion of our convertible notes to 2030, we have completed a shareholder-friendly transaction that significantly enhances our balance sheet flexibility and strengthens our financial position. With our go-forward cash flows and liquidity, we believe we are well positioned to fully fund our pipeline and meet our near-term obligations. This allows us to focus on our base business and the upcoming readouts from our pipeline, including our siRNA programs, as we continue to pursue our mission to transform the lives of patients with rare diseases." The Transactions are expected to close on or about August 28, 2025, subject to customary closing conditions. The issuance of the New Convertible Notes will occur pursuant to an indenture related to the New Convertible Notes, to be dated on or around August 28, 2025, between the Company and U.S. Bank Trust Company, National Association, as trustee. Following the closing of the Exchange, approximately $450.0 million in aggregate principal amount of the Existing Convertible Notes will remain outstanding with terms unchanged. The offer and sale of the New Convertible Notes and Common Stock, including Common Stock issuable upon conversion of the New Convertible Notes, if any, are not being registered under the Securities Act, or any state securities laws. The New Convertible Notes and Common Stock, including Common Stock issuable upon conversion, if any, may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act and any applicable state securities laws. This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the laws of such jurisdiction. J. Wood Capital Advisors LLC is acting as Sarepta's financial advisors in connection with the Exchange. About Sarepta Therapeutics Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. For more information, please visit or follow us on LinkedIn, X, Instagram and Facebook. Internet Posting of Information We routinely post information that may be important to investors in the 'For Investors' section of our website at We encourage investors and potential investors to consult our website regularly for important information about us. Forward-Looking Statements In order to provide Sarepta's investors with an understanding of its current results and future prospects, this press release contains statements that are forward-looking. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as 'believes,' 'anticipates,' 'plans,' 'expects,' 'will,' 'may,' 'intends,' 'prepares,' 'looks,' 'potential,' 'possible' and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements relating to the Transactions, including the timing of the closing of the Transactions. These forward-looking statements involve risks and uncertainties, many of which are beyond Sarepta's control. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: that we may not be able to consummate the Transactions on the anticipated terms, or at all; that we may not be able to execute on our business plans; the estimated impacts of the strategic restructuring plan announced in July 2025; and those risks identified under the heading 'Risk Factors' in our most recent Annual Report on Form 10-K for the year ended December 31, 2024 and our most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company which you are encouraged to review.
